BRPI1013617A2 - derivados de piperidina como antagonistas de receptor de nk3 - Google Patents

derivados de piperidina como antagonistas de receptor de nk3

Info

Publication number
BRPI1013617A2
BRPI1013617A2 BRPI1013617A BRPI1013617A BRPI1013617A2 BR PI1013617 A2 BRPI1013617 A2 BR PI1013617A2 BR PI1013617 A BRPI1013617 A BR PI1013617A BR PI1013617 A BRPI1013617 A BR PI1013617A BR PI1013617 A2 BRPI1013617 A2 BR PI1013617A2
Authority
BR
Brazil
Prior art keywords
receptor antagonists
piperidine derivatives
piperidine
derivatives
antagonists
Prior art date
Application number
BRPI1013617A
Other languages
English (en)
Inventor
Anja Limberg
Claus Riemer
Hasane Ratni
Henner Knust
Matthias Nettekoven
Walter Vifian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1013617A2 publication Critical patent/BRPI1013617A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4465Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI1013617A 2009-03-19 2010-03-16 derivados de piperidina como antagonistas de receptor de nk3 BRPI1013617A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09155585 2009-03-19
PCT/EP2010/053417 WO2010106081A1 (en) 2009-03-19 2010-03-16 Piperidine derivatives as nk3 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI1013617A2 true BRPI1013617A2 (pt) 2016-04-19

Family

ID=42161621

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013617A BRPI1013617A2 (pt) 2009-03-19 2010-03-16 derivados de piperidina como antagonistas de receptor de nk3

Country Status (13)

Country Link
US (1) US8324250B2 (pt)
EP (1) EP2408745B1 (pt)
JP (1) JP5452627B2 (pt)
KR (1) KR101383538B1 (pt)
CN (1) CN102356065B (pt)
AU (1) AU2010224865B2 (pt)
BR (1) BRPI1013617A2 (pt)
CA (1) CA2749650A1 (pt)
ES (1) ES2505190T3 (pt)
IL (1) IL213982A0 (pt)
MX (1) MX2011008850A (pt)
SG (1) SG174876A1 (pt)
WO (1) WO2010106081A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399676B2 (en) * 2009-07-30 2013-03-19 Hoffman-La Roche Inc. Piperidine derivatives
US8258158B2 (en) * 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
CN102827056B (zh) * 2012-09-03 2014-07-23 华东理工大学 N-芳基取代吡咯烷酮衍生物及其用途
WO2014089019A1 (en) * 2012-12-03 2014-06-12 University Of Washington Through Its Center For Commercialization Methods and compositions for treating vasomotor symptoms
KR20160100329A (ko) 2013-12-20 2016-08-23 3-브이 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절물질 및 이들의 조합물
WO2016028971A1 (en) 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
EP3456716A4 (en) * 2016-05-09 2019-11-06 Nippon Soda Co., Ltd. RINGFUL AMID CONNECTION AND PESTICIDES
IL317570A (en) 2022-06-13 2025-02-01 Alivexis Inc Azacycloalkylcarbonyl cyclic amines and their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188747B1 (en) 1999-05-24 2005-09-07 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
EP1372653B1 (en) * 2001-02-28 2006-10-04 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
EP1467995B1 (en) 2001-12-20 2010-05-19 OSI Pharmaceuticals, Inc. Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
EP1622876A1 (en) 2003-05-07 2006-02-08 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
EP1638935A1 (en) * 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
ZA200601175B (en) * 2003-08-15 2007-04-25 Lundbeck & Co As H Cyclopropyl derivatives as NK3 receptor antagonists
BRPI0720246A2 (pt) * 2006-12-07 2013-12-31 Hoffmann La Roche Derivados de espiro-piperidina
US7470684B2 (en) * 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
US8063075B2 (en) * 2008-06-10 2011-11-22 Hoffmann-La Roche Inc. Pyrrolidine ether derivatives as NK3 receptor antagonists

Also Published As

Publication number Publication date
IL213982A0 (en) 2011-08-31
US20100256126A1 (en) 2010-10-07
KR101383538B1 (ko) 2014-04-11
CN102356065A (zh) 2012-02-15
ES2505190T3 (es) 2014-10-09
JP2012520270A (ja) 2012-09-06
AU2010224865A1 (en) 2011-08-11
EP2408745A1 (en) 2012-01-25
MX2011008850A (es) 2011-09-28
CA2749650A1 (en) 2010-09-23
AU2010224865B2 (en) 2013-09-05
KR20110117235A (ko) 2011-10-26
CN102356065B (zh) 2014-10-01
US8324250B2 (en) 2012-12-04
WO2010106081A1 (en) 2010-09-23
SG174876A1 (en) 2011-11-28
EP2408745B1 (en) 2014-07-16
JP5452627B2 (ja) 2014-03-26

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
BRPI1013821A2 (pt) piridinas substituídas como antagonistas de ccr3.
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
BRPI0812981A2 (pt) Derivados de piperidina úteis como antagonistas dos receptores de orexina
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
BRPI1015038A2 (pt) derivados espiro azacíclicos como inibidores de hsl
CO6811856A2 (es) Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
IL208466A0 (en) Isoquinolinone derivatives as nk3 antagonists
BRPI0817061A2 (pt) Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
BRPI0814767A2 (pt) Derivados de monoamida como antagonistas do receptor de orexina
BRPI0815674A2 (pt) Aril-éter de pirrolidina como antagonista de receptor de nk3
BRPI0815658A2 (pt) Aril-éter pirrolidina como antagonistas do receptor nk3
IL213982A0 (en) Piperidine derivatives as nk3 receptor antagonists
BRPI1007369A2 (pt) derivados de di-hidroquinolinona
EP2503066A4 (en) CONSTRUCTION MACHINE
SMT201300020B (it) Derivati di isochinolinone come antagonisti dei recettori nk3
BRPI1016207A2 (pt) compostos de 4-azetidinil-1-heteroaril-ciclohexano antagonistas de ccr2
BR112012003976A2 (pt) antagonistas de receptor glyt1 carbocíclico
BRPI0915834A2 (pt) 6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]